Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Epitalon and GHK — mechanism, dosing, side effects, legal status, and pricing.
Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved and not included in any major Western clinical guideline.
GHK is the parent tripeptide Gly-His-Lys, originally isolated from human plasma by Loren Pickart (1973) as an activity that caused aged hepatocytes to synthesize proteins like younger tissue. It is DISTINCT from GHK-Cu, the 1:1 copper(II) complex tracked as a separate entry — but GHK binds copper readily in vivo, so in physiological environments the bare peptide rapidly associates with available Cu(II). Not FDA-approved for any indication; used in cosmetic and research contexts only.
Epitalon
GHK
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Epitalon
GHK
COA corpus from Disclosed Labs — independently tested batches only.
Epitalon
87
COAs
99.3%
Avg purity
14
Labs
GHK
No COA data yet.
Submit testing data →GHK is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Epitalon remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
The evidence base is dominated by the Khavinson group. A 2003 paper in Bulletin of Experimental Biology and Medicine (Khavinson, Bondarev, Butyugov; PMID 12937682) reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. Additional Khavinson-group papers and reviews (e.g. 'Peptides and Ageing,' PMID 12374906) describe melatonin-rhythm normalization and claimed geroprotective effects in elderly Russian patients treated with epithalamin or epitalon in open-label / small-cohort studies over 6–12 year follow-up. These clinical studies have significant methodological limitations (open-label design, single-center, limited controls) and have NOT been independently replicated in rigorous Western controlled trials. There are no Phase 2/3 trials, no FDA approval, and no inclusion in Western clinical guidelines. Grey-market dosing of 5–10 mg SubQ daily for 10–20 day cycles, 1–2 times per year, is not clinically validated for any endpoint.
Key references
The overwhelming majority of GHK research uses the GHK-Cu complex; direct studies of copper-free GHK are limited. Pickart (J Biomater Sci Polym Ed, 2008, PMID 18644225) reviewed GHK's role in tissue remodeling and wound healing. Pickart et al. (Oxid Med Cell Longev, 2012, PMID 22666519) reviewed GHK-Cu in oxidative stress and cognitive aging. Pickart, Vasquez-Soltero & Margolina (BioMed Res Int, 2014, PMID 25302294; 'GHK and DNA: Resetting the Human Genome to Health') summarized microarray data indicating GHK modulates expression of thousands of human genes. No human clinical trials exist for injected bare GHK; cosmetic formulations typically use topical GHK or GHK-Cu at ~50–200 ppm.
Key references
Epitalon and GHK are both in the Cosmetic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing